 Joshua Yarrow
Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Injuries | 14 | 2022 | 174 | 6.780 |
Why?
| | Testosterone | 25 | 2019 | 336 | 6.580 |
Why?
| | Bone and Bones | 10 | 2022 | 283 | 3.690 |
Why?
| | Muscle, Skeletal | 17 | 2021 | 1459 | 2.420 |
Why?
| | Androgens | 11 | 2018 | 165 | 1.930 |
Why?
| | Dihydrotestosterone | 6 | 2015 | 39 | 1.620 |
Why?
| | Trenbolone Acetate | 7 | 2018 | 7 | 1.460 |
Why?
| | Muscular Atrophy | 3 | 2021 | 76 | 1.370 |
Why?
| | Bone Remodeling | 3 | 2022 | 65 | 1.370 |
Why?
| | Osteogenesis | 2 | 2021 | 184 | 1.230 |
Why?
| | Osteoporosis | 5 | 2015 | 227 | 1.180 |
Why?
| | Rats | 19 | 2022 | 5035 | 1.110 |
Why?
| | Prostate | 4 | 2017 | 157 | 1.090 |
Why?
| | Rats, Sprague-Dawley | 11 | 2022 | 2262 | 1.080 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2018 | 133 | 1.060 |
Why?
| | Finasteride | 5 | 2017 | 35 | 0.960 |
Why?
| | Estradiol | 5 | 2018 | 453 | 0.930 |
Why?
| | Bone Density | 7 | 2022 | 432 | 0.900 |
Why?
| | Exercise | 6 | 2022 | 1611 | 0.850 |
Why?
| | Cancellous Bone | 2 | 2019 | 20 | 0.830 |
Why?
| | Hormone Replacement Therapy | 4 | 2018 | 77 | 0.830 |
Why?
| | Estrogens | 4 | 2018 | 316 | 0.800 |
Why?
| | Ovariectomy | 3 | 2018 | 117 | 0.760 |
Why?
| | Bone Resorption | 2 | 2018 | 74 | 0.750 |
Why?
| | Animals | 29 | 2022 | 32158 | 0.700 |
Why?
| | Relaxin | 1 | 2019 | 15 | 0.670 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 169 | 0.670 |
Why?
| | Skull Fractures | 1 | 2019 | 28 | 0.670 |
Why?
| | X-Ray Microtomography | 4 | 2022 | 79 | 0.660 |
Why?
| | Physical Therapy Modalities | 1 | 2022 | 269 | 0.640 |
Why?
| | Male | 39 | 2022 | 56103 | 0.620 |
Why?
| | Hypertriglyceridemia | 1 | 2018 | 34 | 0.620 |
Why?
| | Neuromuscular Junction | 1 | 2018 | 53 | 0.610 |
Why?
| | Orchiectomy | 6 | 2018 | 57 | 0.610 |
Why?
| | Physical Conditioning, Animal | 1 | 2019 | 191 | 0.600 |
Why?
| | Anabolic Agents | 4 | 2014 | 11 | 0.590 |
Why?
| | Muscle Weakness | 1 | 2018 | 81 | 0.580 |
Why?
| | Arthritis | 1 | 2018 | 110 | 0.570 |
Why?
| | Cholestenone 5 alpha-Reductase | 2 | 2015 | 3 | 0.550 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 448 | 0.540 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 223 | 0.540 |
Why?
| | Recovery of Function | 1 | 2019 | 576 | 0.530 |
Why?
| | Diet, High-Fat | 2 | 2021 | 225 | 0.520 |
Why?
| | Fructose | 1 | 2016 | 100 | 0.510 |
Why?
| | Sarcopenia | 1 | 2015 | 66 | 0.450 |
Why?
| | Muscles | 2 | 2014 | 328 | 0.450 |
Why?
| | Muscle Strength | 5 | 2018 | 278 | 0.450 |
Why?
| | Rats, Inbred F344 | 7 | 2018 | 245 | 0.450 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 193 | 0.440 |
Why?
| | Hypogonadism | 4 | 2015 | 74 | 0.430 |
Why?
| | Hindlimb Suspension | 1 | 2012 | 20 | 0.430 |
Why?
| | Human Growth Hormone | 2 | 2012 | 38 | 0.410 |
Why?
| | Resistance Training | 2 | 2012 | 124 | 0.390 |
Why?
| | Adiponectin | 1 | 2012 | 213 | 0.380 |
Why?
| | Feeding Behavior | 1 | 2016 | 574 | 0.360 |
Why?
| | Hypertension | 1 | 2018 | 1065 | 0.350 |
Why?
| | Physical Endurance | 2 | 2010 | 223 | 0.350 |
Why?
| | Hemoglobins | 2 | 2012 | 313 | 0.340 |
Why?
| | Bone Diseases, Metabolic | 2 | 2021 | 53 | 0.340 |
Why?
| | Lactic Acid | 2 | 2008 | 276 | 0.340 |
Why?
| | Aromatase | 3 | 2015 | 31 | 0.340 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2010 | 106 | 0.340 |
Why?
| | Periodontitis | 2 | 2019 | 42 | 0.330 |
Why?
| | Aging | 2 | 2015 | 1635 | 0.310 |
Why?
| | Physical Education and Training | 1 | 2008 | 60 | 0.310 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 32 | 0.290 |
Why?
| | Weight Lifting | 1 | 2007 | 29 | 0.290 |
Why?
| | Receptors, Androgen | 4 | 2018 | 132 | 0.280 |
Why?
| | 5-alpha Reductase Inhibitors | 2 | 2017 | 16 | 0.270 |
Why?
| | Adiposity | 1 | 2011 | 468 | 0.270 |
Why?
| | Adipose Tissue | 2 | 2021 | 553 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2018 | 1217 | 0.270 |
Why?
| | Atrophy | 2 | 2018 | 152 | 0.260 |
Why?
| | Humans | 27 | 2022 | 115859 | 0.260 |
Why?
| | Obesity | 1 | 2018 | 2523 | 0.260 |
Why?
| | Genetic Markers | 2 | 2018 | 336 | 0.260 |
Why?
| | Organ Size | 5 | 2018 | 434 | 0.250 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 116 | 0.240 |
Why?
| | Adaptation, Physiological | 1 | 2008 | 477 | 0.240 |
Why?
| | Disease Models, Animal | 3 | 2019 | 3587 | 0.220 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 1724 | 0.220 |
Why?
| | Perfusion | 1 | 2022 | 152 | 0.210 |
Why?
| | Body Weight | 4 | 2016 | 868 | 0.200 |
Why?
| | Regeneration | 2 | 2021 | 162 | 0.200 |
Why?
| | Cachexia | 1 | 2021 | 52 | 0.190 |
Why?
| | Exercise Therapy | 3 | 2021 | 353 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2020 | 5 | 0.180 |
Why?
| | Contusions | 1 | 2020 | 19 | 0.180 |
Why?
| | Chemokine CXCL1 | 1 | 2020 | 66 | 0.180 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 162 | 0.170 |
Why?
| | Rats, Inbred Lew | 1 | 2019 | 93 | 0.170 |
Why?
| | Infusions, Subcutaneous | 1 | 2019 | 19 | 0.170 |
Why?
| | Signal Transduction | 5 | 2021 | 4527 | 0.170 |
Why?
| | Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 | 2019 | 1 | 0.170 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 208 | 0.170 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 962 | 0.160 |
Why?
| | Pressure Ulcer | 1 | 2019 | 32 | 0.160 |
Why?
| | Cortical Bone | 1 | 2018 | 18 | 0.160 |
Why?
| | Long-Term Care | 1 | 2019 | 76 | 0.160 |
Why?
| | Post-Concussion Syndrome | 1 | 2021 | 155 | 0.160 |
Why?
| | Bone Density Conservation Agents | 1 | 2019 | 62 | 0.160 |
Why?
| | Drug Administration Routes | 1 | 2018 | 41 | 0.150 |
Why?
| | Multimorbidity | 1 | 2018 | 30 | 0.150 |
Why?
| | Interleukins | 1 | 2020 | 237 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2021 | 246 | 0.150 |
Why?
| | Hypothalamus | 1 | 2018 | 150 | 0.150 |
Why?
| | Prevalence | 3 | 2019 | 2270 | 0.150 |
Why?
| | Hand Strength | 1 | 2018 | 97 | 0.150 |
Why?
| | Growth Hormone | 2 | 2008 | 99 | 0.150 |
Why?
| | Leptin | 1 | 2018 | 211 | 0.150 |
Why?
| | Nutrition Surveys | 1 | 2018 | 225 | 0.140 |
Why?
| | Skin | 1 | 2021 | 668 | 0.140 |
Why?
| | Up-Regulation | 1 | 2020 | 824 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 148 | 0.140 |
Why?
| | Biomarkers | 3 | 2016 | 3474 | 0.140 |
Why?
| | Adult | 7 | 2021 | 30814 | 0.140 |
Why?
| | Aged | 8 | 2021 | 19292 | 0.130 |
Why?
| | Eating | 1 | 2018 | 349 | 0.130 |
Why?
| | Motor Neurons | 1 | 2018 | 213 | 0.130 |
Why?
| | Pilot Projects | 2 | 2011 | 1379 | 0.130 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1244 | 0.130 |
Why?
| | Placebos | 2 | 2014 | 198 | 0.130 |
Why?
| | Adipogenesis | 1 | 2016 | 41 | 0.130 |
Why?
| | Athletic Injuries | 1 | 2021 | 455 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 2 | 2017 | 414 | 0.120 |
Why?
| | Body Composition | 2 | 2016 | 579 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 721 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1137 | 0.120 |
Why?
| | Aromatase Inhibitors | 1 | 2014 | 49 | 0.120 |
Why?
| | Injections | 1 | 2015 | 162 | 0.120 |
Why?
| | Bone Marrow | 1 | 2016 | 248 | 0.120 |
Why?
| | Brain Concussion | 1 | 2021 | 467 | 0.120 |
Why?
| | Injections, Intramuscular | 1 | 2014 | 118 | 0.120 |
Why?
| | Adipocytes | 1 | 2016 | 187 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1443 | 0.120 |
Why?
| | Random Allocation | 1 | 2015 | 337 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 1871 | 0.120 |
Why?
| | Nitriles | 1 | 2014 | 152 | 0.120 |
Why?
| | Triazoles | 1 | 2014 | 131 | 0.110 |
Why?
| | False Positive Reactions | 1 | 2013 | 111 | 0.110 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 4779 | 0.110 |
Why?
| | Middle Aged | 7 | 2021 | 27078 | 0.110 |
Why?
| | Liver | 1 | 2021 | 1693 | 0.110 |
Why?
| | Reference Standards | 1 | 2013 | 162 | 0.110 |
Why?
| | Iron | 1 | 2014 | 235 | 0.110 |
Why?
| | Minerals | 1 | 2012 | 37 | 0.110 |
Why?
| | Double-Blind Method | 2 | 2014 | 1664 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2020 | 2581 | 0.100 |
Why?
| | Prostatic Hyperplasia | 1 | 2012 | 38 | 0.100 |
Why?
| | Absorptiometry, Photon | 1 | 2012 | 221 | 0.100 |
Why?
| | Femur | 2 | 2012 | 194 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2590 | 0.100 |
Why?
| | Age Factors | 1 | 2018 | 2911 | 0.090 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2010 | 60 | 0.090 |
Why?
| | Inflammation | 1 | 2021 | 2502 | 0.090 |
Why?
| | Body Mass Index | 1 | 2018 | 1974 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2011 | 165 | 0.090 |
Why?
| | Organ Specificity | 1 | 2011 | 274 | 0.090 |
Why?
| | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2010 | 9 | 0.090 |
Why?
| | Erythrocytes | 1 | 2014 | 590 | 0.080 |
Why?
| | Osteocalcin | 1 | 2008 | 34 | 0.080 |
Why?
| | Molecular Structure | 1 | 2010 | 447 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2015 | 9163 | 0.080 |
Why?
| | Tensile Strength | 1 | 2008 | 103 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1317 | 0.080 |
Why?
| | Amino Acids | 2 | 2008 | 456 | 0.080 |
Why?
| | Rest | 1 | 2008 | 101 | 0.070 |
Why?
| | Cognition | 1 | 2014 | 980 | 0.070 |
Why?
| | Florida | 1 | 2007 | 73 | 0.070 |
Why?
| | Sex Factors | 1 | 2012 | 1741 | 0.070 |
Why?
| | Biological Availability | 1 | 2007 | 119 | 0.070 |
Why?
| | Physical Exertion | 1 | 2008 | 208 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2404 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2015 | 6434 | 0.070 |
Why?
| | Tibia | 1 | 2008 | 172 | 0.070 |
Why?
| | Female | 7 | 2021 | 60070 | 0.070 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2008 | 151 | 0.070 |
Why?
| | Creatinine | 1 | 2008 | 431 | 0.070 |
Why?
| | Mice | 2 | 2021 | 15085 | 0.070 |
Why?
| | Veterans | 1 | 2017 | 1232 | 0.070 |
Why?
| | Kidney | 2 | 2012 | 1210 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2365 | 0.060 |
Why?
| | Muscle Contraction | 1 | 2008 | 398 | 0.060 |
Why?
| | Exercise Test | 1 | 2007 | 541 | 0.060 |
Why?
| | United States | 1 | 2018 | 12319 | 0.050 |
Why?
| | Murinae | 1 | 2021 | 2 | 0.050 |
Why?
| | Risk Factors | 1 | 2014 | 8715 | 0.050 |
Why?
| | Cicatrix | 1 | 2021 | 50 | 0.050 |
Why?
| | Caseins | 1 | 2019 | 21 | 0.040 |
Why?
| | Sucrose | 1 | 2019 | 91 | 0.040 |
Why?
| | Sigmodontinae | 1 | 2019 | 2 | 0.040 |
Why?
| | Quadriplegia | 1 | 2019 | 12 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2018 | 15 | 0.040 |
Why?
| | Fibrosis | 1 | 2021 | 458 | 0.040 |
Why?
| | Appetite Depressants | 1 | 2018 | 18 | 0.040 |
Why?
| | Wnt-5a Protein | 1 | 2018 | 19 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1218 | 0.040 |
Why?
| | Paralysis | 1 | 2019 | 67 | 0.040 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 174 | 0.040 |
Why?
| | Heptanoates | 1 | 2014 | 2 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2014 | 19 | 0.030 |
Why?
| | CCN Intercellular Signaling Proteins | 1 | 2014 | 5 | 0.030 |
Why?
| | Transferrin | 1 | 2014 | 40 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 57 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1476 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2018 | 643 | 0.030 |
Why?
| | Myosins | 1 | 2014 | 126 | 0.030 |
Why?
| | Anthropometry | 1 | 2014 | 182 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2021 | 1078 | 0.030 |
Why?
| | Drug Interactions | 1 | 2014 | 347 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2014 | 177 | 0.030 |
Why?
| | Receptors, Glucocorticoid | 1 | 2014 | 143 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2014 | 346 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 796 | 0.030 |
Why?
| | Young Adult | 2 | 2021 | 10508 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 643 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2014 | 369 | 0.020 |
Why?
| | Time Factors | 2 | 2014 | 6182 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 414 | 0.020 |
Why?
| | Isotonic Contraction | 1 | 2009 | 2 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 677 | 0.020 |
Why?
| | Adolescent | 1 | 2007 | 17935 | 0.020 |
Why?
| | Databases, Factual | 1 | 2012 | 1137 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2009 | 354 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 4960 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 339 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1227 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2021 | 12615 | 0.020 |
Why?
|
|
Yarrow's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|